There are disclosed pharmaceutical compounds of the formula: ##STR1## in which R.sup.1 is halo-substituted alkyl; X is alkenylene; and R.sup.1 --X-- contains 6 to 34 carbon atoms; R.sup.2 is C.sub.1-5 alkyl substituted by (i) optionally protected carboxyl, nitrile, optionally protected tetrazolyl or --CONR'R", in which R' and R" are each hydrogen or C.sub.1-4 alkyl, ##STR2## (ii) in which R' and R" are each hydrogen or C.sub.1-4 alkyl, or ##STR3## (iii) in which R', R" and R'" are each hydrogen or C.sub.1-4 alkyl, or R.sup.2 is a group of the formula ##STR4## in which R' is hydrogen or an optionally protected amino acid residue, and R" is --OH or an optionally protected amino acid residue; and R.sup.3, R.sup.4 and R.sup.5 are each hydrogen, optionally protected carboxyl, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxyl, optionally protected tetrazolyl, halo, trifluoromethyl, nitrile, nitro or --CONR'R" where R' and R" are each hydrogen or C.sub.1-4 alkyl; and salts thereof.
揭示了具有以下结构的药物化合物:##STR1## 其中R.sup.1是卤代烷基;X是烯基;R.sup.1--X--包含6到34个碳原子;R.sup.2是C.sub.1-5烷基,其被(i) 可选保护的羧基、腈基、可选保护的
四唑基或--CONR'R"取代,其中R'和R"分别是氢或C.sub.1-4烷基,##STR2## (ii) 其中R'和R"分别是氢或C.sub.1-4烷基,或##STR3## (iii) 其中R'、R"和R'"分别是氢或C.sub.1-4烷基,或R.sup.2是具有以下结构的基团##STR4## 其中R'是氢或可选保护的
氨基酸残基,R"是--OH或可选保护的
氨基酸残基;R.sup.3、R.sup.4和R.sup.5分别是氢、可选保护的羧基、C.sub.1-4烷基、C.sub.1-4烷氧基、羟基、可选保护的
四唑基、卤素、三
氟甲基、腈基、硝基或--CONR'R",其中R'和R"分别是氢或C.sub.1-4烷基;以及其盐。